FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33522-US-PCT APPLICATION NO. 10/579,427 APPLICANT BAESCHLIN ET AL. FILING DATE

MAY 12, 2006

10/579,427

Sheet 1 of 1

Group 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SK/	AA	5,559,111	9/24/96	Göschke et al.	514	227	4/4/95
/SK/	AB	5,606,078	2/25/97	Göschke et al.	549	321	4/4/95
/SK/	AC	5,627,182	5/6/97	Göschke et al.	514	237	7/25/96
/SK/	AD	5,646,143	7/8/97	Göschke et al.	514	233	7/25/96
/SK/	AE	5,705,658	1/6/98	Göschke et al.	549	321	2/14/97
	AF						
	AG						
	АН						
	ΑI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
/SK/	AM	WO 02/40007 A	5/23/02	PCT				
/SK/	AN	WO 03/103653 A	12/18/03	PCT				
	AO							
	AP					-		
	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SK/	AR	Wood et al, Biochemical and Biophysical Research Communications 308, pp. 698-705, "Structure-based design of aliskiren, a novel orally effective rennin inhibitor. (2003)				
/SK/	AS	Goeschke et al. Bioorganic & Synthesis of Novel 2,7-Dialkyl as <i>in Vitro</i> Potent Peptidomeir	Medicinal Chemistry Letters, Vol. 7, No. 21, pp 2735-2740, Design and Substituted 5(S)-Amino-4(S)-Hydroxy-8-Phenyl-Octanecarboxamides netic inhibitors of Human Renin 1997.			
	АТ					

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.